

Myeloproliferative Neoplasms Advances Day

Friday 17th November 2017

BMA House, Tavistock Square, London WC1H 9JP



08.45 *Registration and coffee*

Chairs: Claire Harrison & Joanne Ewing

09.15 Introduction

Professor Claire Harrison
Guy's and St Thomas' Hospital, London

09.20 How do we assess prognosis in MPN

Professor Alessandro Vannucchi
University of Florence, Italy

09.45 MPNs – from molecular pathogenesis to personalized predictions

Professor Tony Green
Cambridge University

10.05 Real-world experience of extended molecular testing

Dr Angela Hamblin
Oxford Molecular Diagnostics Centre

10.30 Cerebrovascular thrombosis in myeloproliferative neoplasms

Professor Tiziano Barbui
Ospedali Riuniti di Bergamo, Italy

10.55 Inflammation cause and effect

Professor Steffen Koschmieder
Aachen University, Germany

11.20 *Tea and coffee*

Chairs: Fran Wadelin & Mallika Sekhar

11.40 Pathogenesis and prevention of MPN-related thrombosis

Professor Martin Ellis
Sackler Faculty of Medicine, Tel Aviv, Israel

12.00 SVT – what the haematologists need to know

Dr David Patch
Royal Free Hospital, London

12.20 Use of direct oral anticoagulants in MPN

Professor Hannah Cohen
UCLH, London

12.40 MPN in pregnancy

Dr Susan Robinson
Guy's and St Thomas' Hospital, London

13.00 *Lunch*

Chairs: Donal McLornan, Nauman Butt & Mary Frances McMullin

13.50 BCSH Guideline for eosinophilia

Dr Nauman Butt
Royal Liverpool University Hospital

14.15 Systemic mastocytosis

Dr Deepti Radia
Guy's and St Thomas' Hospital, London

14.45 CMML

Professor Eric Solary
Gustave Roussy, Paris, France

15.10 Treatment free remission in CML

Professor Richard Clark
University of Liverpool

15.35 *Tea and coffee*

15.55 New approaches in managing MPNs

Professor Ruben Mesa
UT San Antonio Cancer Centre, TX, USA

16.20 How I manage myelofibrosis

Professor Francisco Cervantes
Hospital Clínic de Barcelona, Spain

16.45 A forward look at MPN in the UK

Dr Adam Mead
University of Oxford

17.10 *Close*

This conference is kindly sponsored by:



The sponsors have had no influence over the content of the agenda or speaker selection